Incidence and Outcomes of Primary Central Nervous System Lymphoma in Solid Organ Transplant Recipients

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2017 Aug 15

PMID 28805292

Citations 19

Authors

Parag Mahale

Meredith S Shiels

Charles F Lynch

Eric A Engels

Affiliations

Soon will be listed here.

Abstract

Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed human immunodeficiency virus-infected people. Using data from the US transplant registry linked with 17 cancer registries (1987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients. Transplant recipients had elevated incidence for PCNSL compared with the general population (standardized incidence ratio = 65.1; N = 168), and this elevation was stronger than for systemic NHL (standardized incidence ratio=11.5; N = 2043). Compared to kidney recipients, PCNSL incidence was lower in liver recipients (adjusted incidence rate ratio [aIRR] = 0.52), similar in heart and/or lung recipients, and higher in other/multiple organ recipients (aIRR = 2.45). PCNSL incidence was higher in Asians/Pacific Islanders than non-Hispanic whites (aIRR = 2.09); after induction immunosuppression with alemtuzumab (aIRR = 3.12), monoclonal antibodies (aIRR = 1.83), or polyclonal antibodies (aIRR = 2.03); in recipients who were Epstein-Barr virus-seronegative at the time of transplant and at risk of primary infection (aIRR = 1.95); and within the first 1.5 years after transplant. Compared to other recipients, those with PCNSL had increased risk of death (adjusted hazard ratio [aHR] = 11.79) or graft failure/retransplantation (aHR = 3.24). Recipients with PCNSL also had higher mortality than those with systemic NHL (aHR = 1.48). In conclusion, PCNSL risk is highly elevated among transplant recipients, and it carries a poor prognosis.

Citing Articles

Identifying CNS infections in transplantation and immunomodulatory therapy.

Alviz L, Jones B, Agnihotri S, Thakur K Ther Adv Infect Dis. 2024; 11:20499361241298456.

PMID: 39524986 PMC: 11550508. DOI: 10.1177/20499361241298456.

Tumor-like Lesions in Primary Angiitis of the Central Nervous System: The Role of Magnetic Resonance Imaging in Differential Diagnosis.

Zedde M, Napoli M, Moratti C, Pavone C, Bonacini L, Cecco G Diagnostics (Basel). 2024; 14(6).

PMID: 38535038 PMC: 10969781. DOI: 10.3390/diagnostics14060618.

Unpacking the CNS Manifestations of Epstein-Barr Virus: An Imaging Perspective.

Soni N, Ora M, Singh R, Mehta P, Agarwal A, Bathla G AJNR Am J Neuroradiol. 2023; 44(9):1002-1008.

PMID: 37500288 PMC: 10494941. DOI: 10.3174/ajnr.A7945.

Primary central nervous system lymphoma.

Ferreri A, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K Nat Rev Dis Primers. 2023; 9(1):29.

PMID: 37322012 PMC: 10637780. DOI: 10.1038/s41572-023-00439-0.

Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022.

Pons-Escoda A, Naval-Baudin P, Velasco R, Vidal N, Majos C AJNR Am J Neuroradiol. 2023; 44(4):358-366.

PMID: 36822829 PMC: 10084903. DOI: 10.3174/ajnr.A7795.

References

Engels E, Pfeiffer R, Fraumeni Jr J, Kasiske B, Israni A, Snyder J . Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306(17):1891-901. PMC: 3310893. DOI: 10.1001/jama.2011.1592. View

Sola-Valls N, Rodriguez C N, Arcal C, Duran C, Oppenheimer F, Ribalta T . Primary brain lymphomas after kidney transplantation: an under-recognized problem?. J Nephrol. 2014; 27(1):95-102. DOI: 10.1007/s40620-013-0026-z. View

Schabet M . Epidemiology of primary CNS lymphoma. J Neurooncol. 1999; 43(3):199-201. DOI: 10.1023/a:1006290032052. View

Hochberg F, Baehring J, Hochberg E . Primary CNS lymphoma. Nat Clin Pract Neurol. 2007; 3(1):24-35. DOI: 10.1038/ncpneuro0395. View

Traum A, Rodig N, Pilichowska M, Somers M . Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients. Pediatr Transplant. 2006; 10(4):505-12. DOI: 10.1111/j.1399-3046.2006.00497.x. View

Hall E, Engels E, Pfeiffer R, Segev D . Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2014; 99(5):1051-7. PMC: 4405385. DOI: 10.1097/TP.0000000000000449. View

Opelz G, Dohler B . Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4(2):222-30. DOI: 10.1046/j.1600-6143.2003.00325.x. View

Hochberg F, Miller D . Primary central nervous system lymphoma. J Neurosurg. 1988; 68(6):835-53. DOI: 10.3171/jns.1988.68.6.0835. View

Cavaliere R, Petroni G, Lopes M, Schiff D . Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010; 116(4):863-70. PMC: 4113953. DOI: 10.1002/cncr.24834. View

10.

Deckert M, Engert A, Bruck W, Ferreri A, Finke J, Illerhaus G . Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011; 25(12):1797-807. DOI: 10.1038/leu.2011.169. View

11.

Ferreri A, Blay J, Reni M, Pasini F, Spina M, Ambrosetti A . Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21(2):266-72. DOI: 10.1200/JCO.2003.09.139. View

12.

Castellano-Sanchez A, Li S, Qian J, Lagoo A, Weir E, Brat D . Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol. 2004; 121(2):246-53. DOI: 10.1309/N82C-TQ1J-0XEV-EFQB. View

13.

Leblond V, Dhedin N, Mamzer Bruneel M, Choquet S, Hermine O, Porcher R . Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001; 19(3):772-8. DOI: 10.1200/JCO.2001.19.3.772. View

14.

Norden A, Drappatz J, Wen P, Claus E . Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2010; 101(3):487-93. DOI: 10.1007/s11060-010-0269-7. View

15.

Shiels M, Pfeiffer R, Besson C, Clarke C, Morton L, Nogueira L . Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016; 174(3):417-24. PMC: 4961566. DOI: 10.1111/bjh.14073. View

16.

Hanto D, Frizzera G, Purtilo D, Sakamoto K, Sullivan J, Saemundsen A . Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. 1981; 41(11 Pt 1):4253-61. View

17.

Riemersma S, Jordanova E, Schop R, Philippo K, Looijenga L, Schuuring E . Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood. 2000; 96(10):3569-77. View

18.

Penn I, Porat G . Central nervous system lymphomas in organ allograft recipients. Transplantation. 1995; 59(2):240-4. View

19.

Buell J, Gross T, Hanaway M, Trofe J, Roy-Chaudhury P, First M . Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005; 37(2):954-5. DOI: 10.1016/j.transproceed.2004.12.130. View

20.

Chaturvedi A, Mbulaiteye S, Engels E . Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol. 2007; 18(3):230-4. DOI: 10.1016/j.annepidem.2007.10.005. View